GO
Loading...

Eli Lilly and Co

More

  • LONDON, Nov 13- AstraZeneca is developing an antibody treatment to reverse the blood-thinning effect of its heart drug Brilinta in rare emergency situations, such as urgent surgery or in the event of major bleeding. AstraZeneca said on Thursday the experimental antibody product, MEDI2452, was in pre-clinical tests at its MedImmune biotech unit.

  • Final Glance: Pharmaceuticals companies Wednesday, 12 Nov 2014 | 6:02 PM ET

    Baxter International Inc. rose$. 57 or. 8 percent, to $71.33. Bristol-Myers Squibb Co. fell$. 11 or. 2 percent, to $58.61. Hospira rose$. 78 or 1.4 percent, to $58.09.

  • Midday Glance: Pharmaceuticals companies Wednesday, 12 Nov 2014 | 1:23 PM ET

    Baxter International Inc. rose$. 24 or. 3 percent, to $71.00. Bristol-Myers Squibb Co. fell$. 05 or. 1 percent, to $58.67. Johnson& Johnson fell$. 05 or percent, to $108.86.

  • Early Glance: Pharmaceuticals companies Wednesday, 12 Nov 2014 | 11:05 AM ET

    Baxter International Inc. rose$. 09 or. 1 percent, to $70.85. Bristol-Myers Squibb Co. rose$. 05 or. 1 percent, to $58.77. Pfizer rose$. 17 or. 6 percent, to $30.49.

  • Final Glance: Pharmaceuticals companies Tuesday, 11 Nov 2014 | 6:02 PM ET

    Baxter International Inc. rose$. 13 or. 2 percent, to $70.76. Bristol-Myers Squibb Co. fell$. 09 or. 2 percent, to $58.72. Hospira rose $1.33 or 2.4 percent, to $57.31.

  • Midday Glance: Pharmaceuticals companies Tuesday, 11 Nov 2014 | 1:52 PM ET

    Baxter International Inc. rose$. 16 or. 2 percent, to $70.79. Bristol-Myers Squibb Co. fell$. 00 or percent, to $58.81. Hospira rose$. 74 or 1.3 percent, to $56.72.

  • Early Glance: Pharmaceuticals companies Tuesday, 11 Nov 2014 | 10:33 AM ET

    Bristol-Myers Squibb Co. fell$. 04 or. 1 percent, to $58.77. Hospira fell$. 04 or. 1 percent, to $55.94. Johnson& Johnson fell$. 04 or percent, to $108.78.

  • Boehringer and Lilly will continue to jointly develop and market these drugs in 17 countries, including the United States, they said in a statement on Wednesday. A new insulin glargine product, which is approved in Europe, has won tentative approval in the United States. Sanofi SA said on Tuesday that growth in sales of its diabetes drugs would stall next year due...

  • Lilly, Boehringer revise terms of diabetes drugs alliance Wednesday, 29 Oct 2014 | 8:55 AM ET

    Oct 29- Eli Lilly and Co and German drugmaker Boehringer Ingelheim said they had revised the structure of their diabetes alliance for some countries. Under the alliance signed in 2011, the companies had agreed to develop and market diabetes drugs together. Boehringer and Eli Lilly said on Wednesday that they would continue joint development and marketing of...

  • *Fujifilm extends gains, but fund manager says its core business uncertain. It helped drive up Seven& i Holdings Co and Aeon Co 1.0 percent and 0.6 percent, respectively. Outperforming the market was Takeda Pharmaceutical Co, which rose 2.6 percent after a U.S. judge slashed a $9 billion punitive damages award to $36.8 million against it and Eli Lilly& Co over their...

  • Oct 27- A U.S. judge on Monday slashed a $9 billion punitive damages award to $36.8 million against Takeda Pharmaceutical Co and Eli Lilly& Co over their Actos diabetes drug. District Judge Rebecca Doherty in Louisiana in a court filing granted a motion from the drugmakers to reduce the $9 billion in combined punitive damages awarded earlier this year.

  • Oct 23- Eli Lilly and Co said its quarterly earnings plunged 58 percent, hurt by special charges and generic competition for its Cymbalta depression drug, but it affirmed its earlier full-year profit forecast. The U.S. drugmaker on Thursday said it had earned $501 million, or 47 cents per share, in the third quarter. Sales fell 16 percent to $4.88 billion, but topped...

  • Lilly profit plunges as cheaper generics take toll Thursday, 23 Oct 2014 | 6:50 AM ET

    Oct 23- Eli Lilly and Co said its quarterly earnings plunged 58 percent, hurt by special charges and generic competition for its Cymbalta depression drug, but it affirmed its earlier full-year profit forecast. The U.S. drugmaker on Thursday said it had earned $501 million, or 47 cents per share, in the third quarter. Sales fell 16 percent to $4.88 billion, but topped...

  • Oct 16- The benefits of Novartis AG's anti-inflammation drug outweighed the risks in using it to treat a type of psoriasis, staff reviewers at the U.S. Food and Drug Administration said. There were no major safety issues associated with secukinumab, according to the review posted on the FDA website on Thursday- four days before a panel of outside advisers is...

  • *Endo offers $33.25/ share for Auxilium. Oct 9- Endo International Plc brought a successful end to its month-long pursuit of Auxilium Pharmaceuticals Inc, with the smaller rival choosing a sweetened offer over its agreement to buy Canadian eye-drug maker QLT Inc.. "Endo recognizes the value inherent to Xiaflex, given the drug's potential in multiple additional...

  • Oct 6- Alcobra Ltd lost more than half its market value after it said its drug to treat adult attention deficit disorder met the main goals of a late-stage trial- but only after excluding data from patients who reacted positively to a placebo. Alcobra's stock was the biggest loser on the Nasdaq as the results also made it less likely the company would be bought.

  • While Lilly's shares hardly budged on the news, the ADRs of Israel- based XTL Biopharmaceuticals Inc, which is developing its own lupus treatment, nearly tripled to $5.00. About 1.5 million people in the United States are estimated to suffer from lupus, according to the U.S. Centers of Disease Control and Prevention. The U.S. Food and Drug Administration approved...

  • *No EU concerns about Eli Lilly, Novartis deal. In contrast, U.S. drugmaker Eli Lilly's proposed $5.4 billion takeover of Swiss peer Novartis's animal health business triggered no such worries and will be cleared unconditionally, the sources said. Eli Lilly is buying the Novartis unit to strengthen and diversify its Elanco unit.

  • Eli Lilly to drop development of lupus drug Thursday, 2 Oct 2014 | 8:57 AM ET

    Oct 2- Eli Lilly and Co said it would discontinue the development of its lupus drug as the treatment was not found to be effective enough in two late-stage trials. The decision will result in a charge of about 4- 5 cents per share in the third quarter, the company said. Eli Lilly said the decision was not because of any safety concerns.

  • A blast from Martha's past: Waksal plans new IPO Wednesday, 24 Sep 2014 | 7:31 AM ET
    Former ImClone CEO Sam Waksal leaves federal court in New York, June 10, 2003.

    Banned ImClone founder Sam Waksal's new biotech company, Kadmon, has plans to go public. The company aims to file with the SEC by the end of this year.